Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Is Editas Stock a Buy Now?
10:07am, Saturday, 07'th Oct 2023
Editas uses an untraditional gene-editing technique. The company is in the clinical stage with no approved therapies yet.
Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
10:07am, Thursday, 05'th Oct 2023
Biotech stocks are highly risky even when they're notching successes. Issuing stock and taking out debt are not equivalent risks for shareholders.
Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena
02:59am, Tuesday, 03'rd Oct 2023
Editas Medicine's reduced R&D costs and strong cash position provide operational comfort but necessitate future capital, especially amid looming competition from exa-cel. EDIT-301 shows early promise
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
10:00am, Monday, 02'nd Oct 2023
Editas Medicine and CRISPR Therapeutics are racing towards the same market. It looks like Bluebird Bio is going to be the player to beat in that market.
Why Editas Medicine Stock Is Soaring Today
11:21am, Friday, 29'th Sep 2023
Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy targeting s
Are Gene Therapy Stocks The Market's Next Big Winners?
08:06am, Monday, 25'th Sep 2023
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD
1 Gene Editing Stock to Buy Now, and 1 to Sell
08:45am, Saturday, 23'rd Sep 2023
Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs.
Editas Medicine, Inc. (EDIT) Presents at Wells Fargo Securities Healthcare Conference Call Transcript
07:11pm, Thursday, 07'th Sep 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo Securities Healthcare Conference Call September 7, 2023 3:00 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Baisong
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
08:25am, Wednesday, 23'rd Aug 2023
Editas Medicine encountered problems with one of its top candidates last year, while the other still has a long way to go. Intellia Therapeutics has a solid financial position, a partner with big pock
Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus
01:30pm, Thursday, 03'rd Aug 2023
Editas (EDIT) reports mixed second-quarter 2023 results. EDIT-301 studies remain on track to provide updates by the end of the year.
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
07:00am, Wednesday, 26'th Jul 2023
CAMBRIDGE, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on W
Is Editas Medicine Stock a Buy Now?
10:15am, Wednesday, 28'th Jun 2023
Its most advanced drug candidate is still far from regulatory approval. The small-cap biotech could run into funding problems ahead.
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
10:23am, Tuesday, 20'th Jun 2023
Editas Medicine is issuing new stock, and that made its share price fall. The new funds will pay for less than one full year of operating expenses.
Editas (EDIT) Surges 15.5%: Is This an Indication of Further Gains?
07:53am, Wednesday, 14'th Jun 2023
Editas (EDIT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength dow
Editas Medicine, Inc. (EDIT) EDIT-301 Clinical Update Call Transcript
03:11pm, Monday, 12'th Jun 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) EDIT-301 Clinical Update Conference Call June 12, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications & Investor Relations Gilmore O'Nei
